Vericel director exercises options, sells shares
Vericel Corp director Kevin F. McLaughlin exercised 7,000 stock options on August 12, 2026 at an exercise price of $13.05 per share, receiving 7,000 common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vericel Corp director Kevin F. McLaughlin exercised 7,000 stock options on August 12, 2026 at an exercise price of $13.05 per share, receiving 7,000 common shares. On the same date he sold 7,000 common shares at $44.53 per share in an automatic sale under a Rule 10b5-1 trading plan adopted on May 12, 2025. The exercised options were part of a grant originally covering 17,500 shares that vested in monthly installments.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,000 shares ($220K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
MCLAUGHLIN KEVIN F
Role
Director
Sold
7,000 shs ($312K)
Approx. gross sale proceeds
$312K
Approx. exercise cost
$91K
Approx. pre-tax spread
$220K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 7,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,000 | $13.05 | $91K |
| Sale | Common Stock F1 | 7,000 | $44.53 | $312K |
Holdings After Transaction:
Stock Option (Right to Buy) — 7,000 contracts (Direct);
Common Stock — 18,300 shares (Direct)
Footnotes (2)
- F1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.
- F2. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.
Key Figures
Options exercised: 7,000 shares
Option exercise price: $13.05 per share
Shares sold: 7,000 shares
+3 more
6 metrics
Options exercised
7,000 shares
Stock options exercised on August 12, 2026
Option exercise price
$13.05 per share
Exercise price of stock options converted into common stock
Shares sold
7,000 shares
Common stock sold on August 12, 2026
Sale price
$44.53 per share
Price for the 7,000 Vericel common shares sold
Original option grant size
17,500 shares
Options granted May 2, 2018, vesting monthly over one year
Option expiration date
May 2, 2028
Expiration of the stock option reported as a derivative security
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), derivative security, automatic sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"automatic sale pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
automatic sale financial
"The sales reported in this Form 4 were effected by an automatic sale"
common stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Vericel (VCEL) director Kevin McLaughlin report in this Form 4?
Kevin F. McLaughlin reported exercising 7,000 stock options at $13.05 per share and selling 7,000 Vericel (VCEL) common shares at $44.53 per share on August 12, 2026, in transactions tied to a previously adopted Rule 10b5-1 trading plan.
How many Vericel (VCEL) options did Kevin McLaughlin exercise and at what price?
He exercised 7,000 stock options in Vericel (VCEL) on August 12, 2026 at an exercise price of $13.05 per share. These options were part of a grant originally covering 17,500 shares that vested monthly over one year, contingent on continued service.
Was the Vericel (VCEL) insider sale made under a Rule 10b5-1 trading plan?
Yes. The Form 4 states the 7,000-share sale of Vericel (VCEL) common stock at $44.53 per share was effected automatically pursuant to a Rule 10b5-1 trading plan that Kevin F. McLaughlin adopted on May 12, 2025, before these transactions occurred.
What is the origin of the Vericel (VCEL) options exercised by Kevin McLaughlin?
The exercised options come from a grant originally covering 17,500 shares of Vericel (VCEL) common stock. This grant was awarded on May 2, 2018 and became exercisable in equal monthly installments over one year, subject to Mr. McLaughlin’s continued service with the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
